The short answer
Canagliflozin can transiently increase urinary sodium loss, but that does not establish a routine need for sodium supplements or special salt timing. The sodium and fluid plan should reflect the person’s kidney and cardiovascular care.
What this answer covers
Dietary sodium versus sodium salts or replacement therapy; no blanket high-salt or sodium-pill recommendation.
- Supplement or preparation
- Sodium
- Medication ingredient
- canagliflozin
Early sodium loss was transient
A small six-day study found increased urinary sodium and urine volume mainly on the first day, with later return toward baseline despite continued urinary glucose loss. This was not a sodium-replacement trial.
Volume change does not prove deficiency
A placebo-controlled study found an early plasma-volume reduction that largely attenuated by twelve weeks. The drug’s volume-depletion warning supports clinical assessment, not automatic sodium supplementation.
Dietary associations are not a salt prescription
A post hoc CREDENCE analysis found that estimated sodium intake related differently to some outcomes depending on treatment. Sodium intake was not randomized, and the analysis cannot justify deliberately increasing salt or abandoning an existing restriction.
Keep the individualized plan
Discuss dizziness, poor intake or fluid-loss illness with the clinician. Follow the prescribed sodium and fluid advice, particularly with kidney or heart disease. No protective sodium-dosing interval or fixed replacement amount is established.
Evidence and practical considerations
Timing & monitoring
Transient natriuresis and volume monitoring do not establish routine sodium need/timing; observational dietary-sodium analysis cannot prescribe salt intake.
- Exact scope
- Dietary sodium versus sodium salts or replacement therapy; no blanket high-salt or sodium-pill recommendation. with Oral canagliflozin RxCUI1373458 IN; agent-specific renal and metabolic mechanisms.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No arbitrary interval, class-only metabolism assumption or unmeasured pair-event rate.
Factors that may matter: Preparation; Dose; Kidney function; Volume status; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral canagliflozin
SGLT2 inhibition increases urinary glucose. Volume contraction can cause hypotension or acute kidney injury, with risk modifiers. UGT inducers may lower drug exposure and effectiveness. Insulin/secretagogue co-use increases hypoglycemia risk.
How this applies: Exact single-ingredient canagliflozin, not all SGLT2 agents or combination products.
Warnings do not establish every botanical interaction or routine sodium supplementation. Renal function and whole regimen matter.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 13Japanese type2diabetes participants,12completed.
Urine volume and sodium excretion rose on day1, then returned toward baseline despite sustained glycosuria.
How this applies: Exact canagliflozin and supplement preparation/endpoint boundaries retained.
Small uncontrolled short study, not a sodium-replacement trial or evidence of universal clinical deficiency.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 36type2diabetes participants.
Early plasma-volume reduction largely attenuated by week12 while urinary glucose effects persisted.
How this applies: Exact canagliflozin and supplement preparation/endpoint boundaries retained.
Small study; volume change is not a proven sodium-pill requirement or herb interaction.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Type2diabetes with chronic kidney disease.
Post hoc associations of estimated sodium intake with cardiovascular outcomes varied by canagliflozin assignment; renal benefit present across sodium groups.
How this applies: Exact canagliflozin and supplement preparation/endpoint boundaries retained.
Sodium intake not randomized; urine-based estimation, confounding and subgroup analyses preclude a causal salt-intake recommendation.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact canagliflozin article separating volume effects, metabolic exposure and intrinsic supplement risks. | |
| Research summary published |
Article revision: 324f732a734d7391
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.